AG百家乐代理-红桃KAG百家乐娱乐城_百家乐筹码片_新全讯网网址xb112 (中国)·官方网站

周啟璠，浙江臺州人，現任南方科技大學格拉布斯研究院研究助理教授（副研究員），生物技術副高級工程師。2019年于沈陽藥科大學獲得藥物化學專業博士學位，師從陳國良教授，并榮獲國家獎學金。主要從事腫瘤、病毒和炎癥相關疾病的小分子創新藥物研究與開發。于2020年加入南方科技大學張緒穆教授課題組，作為項目骨干完成新型口服抗新冠藥物SHEN26的臨床前研究工作，目前已完成III期臨床試驗進入上市申請階段。以一作(含共一)或通訊在STM, STTT, EJMC, JOC等期刊發表SCI文章20余篇，申請發明專利20余項，其中作為主要發明人獲得中國專利授權10項。

研究領域：

1. 基于病毒共性靶標的小分子藥物開發；

2. 發展基于新機制、新靶點的抗腫瘤、抗炎和抗病毒小分子抑制劑

學術成果：

1. Yongzhi Chen¹, Kunyu Lu¹, Binhao Rong¹, Yuanmei Wen, Guanguan Li, Shuo Li, Deyin Guo, Qifan Zhou*, Shuwen Liu*, Xumu Zhang*. Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment. Journal of Medicinal Chemistry, 2024, https://doi.org/10.1021/acs.jmedchem.4c01979.

2. Fan Pan¹, Qifan Zhou^*,1, Ming Yan¹, Sidi Yang¹, Ruiyu Hu, Yongzhi Chen, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Yingjun Li, Hongmin Zhang*, Deyin Guo*, Xumu Zhang*. Development of pyrimidone derivatives as nonpeptidic and noncovalent 3-chymotrypsin-like protease (3CLpro) inhibitors with anti-coronavirus activities. Bioorganic Chemistry, 2024, 154, 107988.

3. Yongzhi Chen¹, Qifan Zhou^**,1, Fan Pan, Binhao Rong, Renwei Xiao, Yuanmei Wen, Jingyuan Song, Zhengchao Tu, Shuwen Liu****, Yingjun Li***, Xumu Zhang*. Synthesis and anti-influenza virus activity of substituted dibenzoxepine-based baloxavir derivatives. European Journal of Medicinal Chemistry, 2024, 280, 116922.

4. Qishu Chen¹, Qifan Zhou^1,*, Sidi Yang¹, Fan Pan, Hongqi Tao, Yuanmei Wen, Yang Chao, Cailing Xie, Weixin Ou, Deyin Guo*, Yingjun Li*, Xumu Zhang*. Identification of adenosine analogues as nsp14 N7?methyltransferase inhibitors for treating coronaviruses infection. Bioorganic Chemistry, 2024, 153, 107894.

5. Qishu Chen¹, Qifan Zhou¹, Guanguan Li, Shuo Li, Yingjun Li* and Xumu Zhang*. Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19. Organic Process Research & Development. 2024, 28, 2188-2195.

6. Qifan Zhou¹, Sidi Yang¹, Liu Cao¹, Yang Yang¹, Tiefeng Xu, Qishu Chen, Hongzhou Lu, Yingjun Li*, Deyin Guo*, Xumu Zhang*. Preclinical characterization of SHEN26, an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside for the treatment of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2023, 8, 27. 

7. Qifan Zhou¹, Yinzhu Luo¹, Yujun Zhu¹, Qishu Chen, Jingfei Qiu, Feng Cong*, Yingjun Li*, Xumu Zhang*. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry, 2023, 249.

8. Liu Cao¹, Yingjun Li¹, Sidi Yang¹, Guanguan Li¹, Qifan Zhou¹, Jing Sun¹, et al. The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. Science Translational Medicine, 2022, 14, eabm7621. 

9. Qifan Zhou, Lina Jia, Fangyu Du, Xiaoyu Dong, Wanyu Sun, Lihui Wang, Guoliang Chen*. Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry, 2020, 44, 2247-2255. 

10. Fangyu Du¹, Qifan Zhou¹, Wenjiao Sun, Cheng Yang, Chunfu Wu, Lihui Wang* and Guoliang Chen*. 5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions. Molecules, 2020, 25, 2059–2083.

11. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Wenjiao Sun, Ying Wu, Guoliang Chen*. L-(-)-Quebrachitol as a ligand for selective copper (0)-catalyzed N?arylation of nitrogen-containing heterocycles. Journal of Organic Chemistry, 2019, 84, 8160–8167. 

12. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Guoliang Chen*. “On Water” promoted N-arylation reactions using Cu (0)/myo-inositol catalytic system. Tetrahedron Letters, 2019, 60, 1938–1941. 

13. Chunling Yuan¹, Xiaoli Guo¹, Qifan Zhou¹, Fangyu Du, Xiaoyu Zhou, Peng Liu, Tianyan Chi, Xuefei Ji, Jinheng Gao, Chengwen Chen, Hongli Lang, Jia Xu, Danyang Liu, Yang Yang, Shimeng Qiu, Guoliang Chen* and Libo Zou*. OAB-14, a novel small molecule, improves Alzheimer’s disease-related pathologies and cognitive impairments by increasing -amyloid clearance in APP/PS1 mice. BBA-Molecular Basis of Disease, 2019, 1865, 161–180. 

14. Yajie Shi¹, Qifan Zhou¹, Fangyu Du, Yang Fu, Yang Du, Ting Fang and Guoliang Chen*. Iridium-catalyzed intramolecular C-N and C-O/S cross-coupling reactions: Preparation of benzoazole derivatives. Tetrahedron Letters, 2019, 60, 151082–151090. 

15. Fangyu Du¹, Qifan Zhou¹, Yang Fu, Yuanguang Chen, Ying Wu* and Guoliang Chen*. Copper(II)-catalyzed C–N coupling of aryl halides and N-nucleophiles promoted by quebrachitol or diethylene glycol. Synlett, 2019, 30, 2161–2168. 

16. Fangyu Du¹, Qifan Zhou¹, Yang Fu, Hanqi Zhao, Yuanguang Chen and Guoliang Chen*. tert-Butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a green and chemoselective N–tert-butoxycarbonylation reagent. New Journal of Chemistry, 2019, 43, 6549–6554. 

17. Fangyu Du, Qifan Zhou, Xiaoxiao Fu, Yajie Shi, Yuanguang Chen, Wuhong Fang, Jingyu Yang* and Guoliang Chen*. Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents. RSC Advances, 2019, 9, 2498–2508. 

18. Fangyu Du, Qifan Zhou, Wenjiao Sun and Guoliang Chen*. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World Journal of Stem Cells, 2019, 11, 398–420. 

19. Fangyu Du, Qifan Zhou, Yajie Shi, Miao Yu, Wenjiao Sun and Guoliang Chen*. Synthesis of regorafenib through novel preparation of the intermediate 4-amino-3-fluorophenol via fries and Beckman rearrangements. Synthetic Communications, 2019, 49, 576–586. 

20. Caijiao Wu1, Qifan Zhou1, Dake Song, Hui Li, Changshun Bao, Xuelong Liu, Xuefei Bao and Guoliang Chen*. An improved process for the preparation of pimavanserin tartrate. Journal of Chemical Research, 2019, 43, 480-485. 

21. Qifan Zhou, Chen Peng, Fangyu Du, Linbo Zhou, Yajie Shi, Yang Du, Dongdong Liu, Wenjiao Sun, Meixia Zhang*, Guoliang Chen*. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. European Journal of Medicinal Chemistry, 2018, 151, 39-50. 

22. Qifan Zhou, Fangyu Du, Xinjie Liang, Wenqiang Liu, Ting Fang and Guoliang Chen*. Zinc (II)-mediated selective O-benzylation of 2-oxo-1,2-dihydropyridines systems. Molecules, 2018, 23, 1784-1798. 

23. Qifan Zhou, Fangyu Du, Yajie Shi, Wenqiang Liu, Dongdong Liu and Guoliang Chen*. An efficient protocol for the production of pymetrozine via a new synthetic strategy. Journal of Chemical Research, 2018, 42, 395-446. 

24. Qifan Zhou, Fangyu Du, Yajie Shi, Ting Fang, Guoliang Chen*. The synthesis and analysis of 1-methyl-4-phenyl-1H-imidazol-2-amine and by-products. Journal of Chemical Research, 2018, 42, 608–610. 

25. Fangyu Du, Qifan Zhou, Dongdong Liu, Ting Fang, Yajie Shi, Yang Du, Guoliang Chen*. Dimerization of aromatic compounds using palladium-carbon catalyzed Suzuki–Miyaura cross-coupling by one-pot synthesis. Synlett, 2018, 29, 779-784.